“Porem ipsum dolor sit amet, consectetur adipiscing elit. Nunc vulputate libero et velit interdum, ac aliquet odio mattis. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.”
Dr. Andy Crew is a seasoned freelance expert in drug discovery with extensive experience in induced proximity. Formerly, Dr. Crew served as the Chief Technology Officer (CTO) at Siduma Therapeutics and Arvinas. During his tenure at Siduma Therapeutics, Dr. Crew was instrumental in the development of a novel class of induced proximity molecules aimed at targeting extracellular proteins.
At Arvinas, where he was the first employee and CTO, he assembled and led a groundbreaking team. This team overcame widespread industry skepticism to unveil the secrets of oral bioavailability and blood-brain barrier penetration for a new category of 'large' heterobifunctional molecule degraders known as PROTACs, successfully advancing the first of these molecules into clinical development.
Dr. Crew brings over 20 years of experience in traditional small molecule development, having led multidisciplinary project teams at Astellas/OSI. His efforts have resulted in the delivery of clinical development candidates and backup agents for the oncology pipeline, targeting mTORC1/2, PTK2, cKit, and KDR.
Additionally, as a group leader at Tularik in the UK, Dr. Crew focused intensely on structure-based drug discovery targeting the FXa, FVIIa, and uPA serine proteases, aimed at treating cardiovascular diseases and cancer.
